HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

<ul>
<li>Laekna’s development mode is mainly based on license-in. However, the increasingly low cost performance of in-licensed products and potential legal risks have made the capital “reconsider”. </li>
<li>Both two core products LAE002 and LAE001 have to face the challenge of market acceptance and potential R&amp;D failure risks. China’s NRDL negotiation further casts doubts on their commercialization prospects.</li>
<li>So, the investment in Laekna may not generate expected return. Together with the unfriendly external environment, we are conservative about <a href="https://www.smartkarma.com/entities/laekna-inc" target="_blank" data-smartkarma-citation="entities:36029:1" rel="noopener">Laekna (LAEKNA HK)</a>’s outlook at the current stage.</li>
</ul>


Laekna’s development mode is mainly based on license-in. However, the increasingly low cost performance of in-licensed products and potential legal risks have made the capital “reconsider”. 
Both two core products LAE002 and LAE001 have to face the challenge of market acceptance and potential R&amp;D failure risks. China’s NRDL negotiation further casts doubts on their commercialization prospects.
So, the investment in Laekna may not generate expected return. Together with the unfriendly external environment, we are conservative about Laekna (LAEKNA HK)’s outlook at the current stage.


Pre-IPO Laekna - Low Cost Performance of License-In Mode Leads to A "Rethink" Of Investment Value

China

Laekna is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer, metabolic diseases, and liver fibrosis. Its pipeline includes drug candidates such as LAE002 for breast and prostate cancer, LAE001 for prostate cancer, and LAE102 for obesity. The company was founded in 2016 and is headquartered in Yuyao, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Laekna (2105 HK)

Pre-IPO Laekna - Low Cost Performance of License-In Mode Leads to A "Rethink" Of Investment Value

Laekna is mainly based on license-in mode,whose increasingly low cost performance and potential legal risks have made the capital “reconsider”.The...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)